- Home
- KNDI vs HLVX Comparison
KNDI vs HLVX Comparison
Compare KNDI & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNDI
- HLVX
- Stock Information
- Founded
- KNDI 2002
- HLVX 2020
- Country
- KNDI China
- HLVX United States
- Employees
- KNDI N/A
- HLVX N/A
- Industry
- KNDI Auto Manufacturing
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- KNDI Consumer Discretionary
- HLVX Health Care
- Exchange
- KNDI Nasdaq
- HLVX Nasdaq
- Market Cap
- KNDI 96.3M
- HLVX 83.7M
- IPO Year
- KNDI N/A
- HLVX 2022
- Fundamental
- Price
- KNDI $1.18
- HLVX $2.12
- Analyst Decision
- KNDI
- HLVX Hold
- Analyst Count
- KNDI 0
- HLVX 5
- Target Price
- KNDI N/A
- HLVX $2.33
- AVG Volume (30 Days)
- KNDI 109.2K
- HLVX 434.4K
- Earning Date
- KNDI 08-15-2025
- HLVX 08-07-2025
- Dividend Yield
- KNDI N/A
- HLVX N/A
- EPS Growth
- KNDI N/A
- HLVX N/A
- EPS
- KNDI N/A
- HLVX N/A
- Revenue
- KNDI $127,569,613.00
- HLVX N/A
- Revenue This Year
- KNDI N/A
- HLVX N/A
- Revenue Next Year
- KNDI N/A
- HLVX N/A
- P/E Ratio
- KNDI N/A
- HLVX N/A
- Revenue Growth
- KNDI 3.21
- HLVX N/A
- 52 Week Low
- KNDI $0.89
- HLVX $1.34
- 52 Week High
- KNDI $2.07
- HLVX $2.16
- Technical
- Relative Strength Index (RSI)
- KNDI 52.54
- HLVX 63.08
- Support Level
- KNDI $1.09
- HLVX $1.98
- Resistance Level
- KNDI $1.17
- HLVX $2.12
- Average True Range (ATR)
- KNDI 0.07
- HLVX 0.08
- MACD
- KNDI 0.01
- HLVX 0.01
- Stochastic Oscillator
- KNDI 61.23
- HLVX 89.66
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.